The MDD treatment landscape is currently undergoing a meaningful transformation. Beyond traditional monoamine-based antidepressants, the market is witnessing growing interest in rapid-acting therapies, NMDA receptor modulators, neuroplasticity-focused approaches, and next-generation treatments targeting novel pathways. The commercial success of ketamine-derived therapies